NEU 0.35% $20.17 neuren pharmaceuticals limited

Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial, page-30

  1. 3,217 Posts.
    lightbulb Created with Sketch. 7031
    It was because the size and costs of doing this type of trial is far bigger thanks NEU’s checkbook,

    But don’t exclude the possibility of a partnering deal dropping out of the blue one day.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.